loading
前日終値:
$5.41
開ける:
$5.41
24時間の取引高:
486.69K
Relative Volume:
0.41
時価総額:
$839.43M
収益:
$62.04M
当期純損益:
$-533.34M
株価収益率:
-1.3393
EPS:
-3.92
ネットキャッシュフロー:
$-473.07M
1週間 パフォーマンス:
-15.42%
1か月 パフォーマンス:
-8.92%
6か月 パフォーマンス:
-45.73%
1年 パフォーマンス:
-45.50%
1日の値動き範囲:
Value
$5.08
$5.45
1週間の範囲:
Value
$5.04
$6.29
52週間の値動き範囲:
Value
$4.95
$14.45

Vir Biotechnology Inc Stock (VIR) Company Profile

Name
名前
Vir Biotechnology Inc
Name
セクター
Healthcare (1153)
Name
電話
415-906-4324
Name
住所
1800 OWENS STREET, SAN FRANCISCO, CA
Name
職員
408
Name
Twitter
@Vir_Biotech
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
VIR's Discussions on Twitter

VIR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
VIR
Vir Biotechnology Inc
5.24 839.43M 62.04M -533.34M -473.07M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
431.67 128.25B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
538.81 63.70B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
547.58 39.07B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.01 33.27B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
230.82 27.58B 3.81B -644.79M -669.77M -6.24

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-01-29 ダウングレード JP Morgan Overweight → Neutral
2023-09-08 ダウングレード BofA Securities Buy → Neutral
2023-03-06 アップグレード JP Morgan Neutral → Overweight
2023-02-21 アップグレード Goldman Neutral → Buy
2023-01-27 アップグレード Morgan Stanley Underweight → Equal-Weight
2022-09-14 開始されました SVB Leerink Outperform
2022-09-09 開始されました Morgan Stanley Underweight
2022-03-03 アップグレード Robert W. Baird Underperform → Neutral
2021-12-21 ダウングレード Robert W. Baird Neutral → Underperform
2021-10-25 アップグレード JP Morgan Underweight → Neutral
2021-09-22 ダウングレード Goldman Buy → Neutral
2021-06-04 再開されました Robert W. Baird Neutral
2021-01-27 ダウングレード JP Morgan Neutral → Underweight
2021-01-20 繰り返されました H.C. Wainwright Buy
2020-10-05 開始されました BofA Securities Buy
2020-09-14 アップグレード Goldman Neutral → Buy
2020-09-11 アップグレード JP Morgan Underweight → Neutral
2020-08-20 開始されました Needham Buy
2020-03-19 ダウングレード JP Morgan Neutral → Underweight
2020-03-13 ダウングレード Goldman Buy → Neutral
2020-02-27 ダウングレード Robert W. Baird Neutral → Underperform
2020-02-04 ダウングレード JP Morgan Overweight → Neutral
2019-11-14 開始されました Robert W. Baird Neutral
2019-11-05 開始されました Barclays Overweight
2019-11-05 開始されました Cowen Outperform
2019-11-05 開始されました Goldman Buy
2019-11-05 開始されました JP Morgan Overweight
すべてを表示

Vir Biotechnology Inc (VIR) 最新ニュース

pulisher
09:56 AM

Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Treatment - GuruFocus

09:56 AM
pulisher
08:44 AM

Vir Biotechnology Presents Promising Phase 2 Hepatitis B Data - TipRanks

08:44 AM
pulisher
08:18 AM

Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Call Transcript - Insider Monkey

08:18 AM
pulisher
08:15 AM

Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha

08:15 AM
pulisher
06:50 AM

Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress - TipRanks

06:50 AM
pulisher
06:31 AM

Vir Biotechnology (VIR) Unveils Promising Hepatitis B Treatment Data | VIR Stock News - GuruFocus

06:31 AM
pulisher
06:17 AM

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | VIR Stock News - GuruFocus

06:17 AM
pulisher
06:00 AM

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - Business Wire

06:00 AM
pulisher
May 08, 2025

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha

May 08, 2025
pulisher
May 08, 2025

Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus - MSN

May 08, 2025
pulisher
May 08, 2025

Vir Biotechnology Reports Q1 2025 Financial Results - TipRanks

May 08, 2025
pulisher
May 08, 2025

Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Advancements - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Vir Biotechnology Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025
pulisher
May 08, 2025

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results - BioSpace

May 08, 2025
pulisher
May 07, 2025

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Earnings call transcript: Vir Biotech Q1 2025 reports increased R&D expenses - Investing.com

May 07, 2025
pulisher
May 07, 2025

Vir Biotechnology (VIR) Falls Short on Q1 Revenue, Advances Clinical Programs | VIR Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 1c - StreetInsider

May 07, 2025
pulisher
May 06, 2025

Vir Biotechnology Q1 2025 Earnings Preview - MSN

May 06, 2025
pulisher
May 06, 2025

Earnings Outlook For Vir Biotechnology - Nasdaq

May 06, 2025
pulisher
May 05, 2025

Vir Biotechnology Inc expected to post a loss of 84 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 05, 2025

(VIR) On The My Stocks Page - news.stocktradersdaily.com

May 05, 2025
pulisher
May 03, 2025

BlackRock, Inc. Reduces Stake in Vir Biotechnology Inc. - GuruFocus

May 03, 2025
pulisher
May 01, 2025

Will Vir Biotech's Hepatitis B And D Data Presentations Give The Stock A Much-Needed Boost? - RTTNews

May 01, 2025
pulisher
Apr 30, 2025

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 - BioSpace

Apr 30, 2025
pulisher
Apr 25, 2025

Vir Biotechnology SVP sells shares for $14,291 - MSN

Apr 25, 2025
pulisher
Apr 25, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver Congress 2025 - marketscreener.com

Apr 25, 2025
pulisher
Apr 24, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 - BioSpace

Apr 24, 2025
pulisher
Apr 24, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 | VIR Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 19, 2025

When (VIR) Moves Investors should Listen - news.stocktradersdaily.com

Apr 19, 2025
pulisher
Apr 17, 2025

5 Analysts Have This To Say About Vir Biotechnology - Benzinga

Apr 17, 2025
pulisher
Apr 16, 2025

Lobbying Update: $50,000 of VIR BIOTECHNOLOGY INC. lobbying was just disclosed - Nasdaq

Apr 16, 2025
pulisher
Apr 10, 2025

New Mpro inhibitors revealed in Vir Biotechnology patent - BioWorld MedTech

Apr 10, 2025
pulisher
Apr 09, 2025

Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple - Insider Monkey

Apr 09, 2025
pulisher
Apr 08, 2025

10 Stocks Under $10 that Will Triple - Insider Monkey

Apr 08, 2025
pulisher
Apr 05, 2025

Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock By Investing.com - Investing.com South Africa

Apr 05, 2025
pulisher
Apr 04, 2025

Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock - Investing.com

Apr 04, 2025
pulisher
Apr 04, 2025

Vir Biotechnology CEO Sells Shares to Cover Tax Obligations - TradingView

Apr 04, 2025
pulisher
Apr 03, 2025

Vir Biotechnology stock hits 52-week low at $6.07 By Investing.com - Investing.com Australia

Apr 03, 2025
pulisher
Apr 03, 2025

Vir Biotechnology stock hits 52-week low at $6.07 - Investing.com

Apr 03, 2025
pulisher
Apr 01, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution - simplywall.st

Mar 31, 2025
pulisher
Mar 28, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company - Yahoo

Mar 28, 2025
pulisher
Mar 26, 2025

Vir Biotechnology stock hits 52-week low at $6.54 By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Vir Biotechnology stock hits 52-week low at $6.54 - Investing.com India

Mar 26, 2025
pulisher
Mar 24, 2025

(VIR) Trading Advice - news.stocktradersdaily.com

Mar 24, 2025
pulisher
Mar 21, 2025

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - Quantisnow

Mar 21, 2025
pulisher
Mar 21, 2025

Brii Bio Secures 4-Year Cash Runway Despite Wider Losses: Key HBV Trial Success - Stock Titan

Mar 21, 2025
pulisher
Mar 20, 2025

Hepatitis D Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com

Mar 20, 2025
pulisher
Mar 13, 2025

(VIR) Trading Signals - Stock Traders Daily

Mar 13, 2025

Vir Biotechnology Inc (VIR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$19.85
price up icon 2.11%
$65.33
price down icon 0.83%
$33.23
price up icon 0.27%
$24.65
price up icon 1.48%
$94.78
price up icon 2.13%
biotechnology ONC
$234.59
price up icon 1.01%
大文字化:     |  ボリューム (24 時間):